The risk of hepatitis B virus reactivation is considerably high during sorafenib therapy in patients with advanced hepatocellular carcinoma
2017 ◽
Vol 66
(1)
◽
pp. S449-S450
◽
1987 ◽
Vol 2
(6)
◽
pp. 533-537
◽
2018 ◽
Vol 217
(6)
◽
pp. 857-860
◽
2007 ◽
Vol 69
(3)
◽
pp. 813-819
◽
2012 ◽
Vol 8
(4)
◽
pp. 356-361
◽